Group B Streptococcus Prevention
Minervax ApS focuses on clinical research in the prevention of Group B streptococcal infection, with studies centered on immunisation strategies for healthy women and pregnant women.
- GBS vaccine development
- Maternal immunisation
- Infection prevention
The sponsor’s trials examine immune protection against GBS and the durability of antibody responses relevant to maternal and neonatal protection.
Combination Vaccination
Another key area of interest is the evaluation of coadministration with Tdap vaccine, reflecting work on how candidate GBS immunisation can be integrated with established maternal vaccination practice.
- Vaccine coadministration
- Tdap compatibility
- Immune response assessment
These studies address the interaction between GBS-NN/NN2 and routine maternal vaccines in healthy non-pregnant and pregnant populations.
Immunogenicity and Antibody Persistence
Minervax ApS also investigates the strength and persistence of vaccine-induced IgG antibody responses, with attention to AlpCN, RibN, Alp1N, and Alp2 3N targets.
- IgG persistence
- Antibody specificity
- Humoral immunity
This work supports understanding of how long vaccine-related protection may remain detectable after primary GBS immunisation.
Maternal and Women’s Health
The sponsor’s clinical programme includes healthy women of childbearing age and pregnant women, placing its research at the intersection of maternal health and infectious disease prevention.
- Pregnancy-related vaccination
- Women’s health
- Neonatal infection prevention
Its research landscape is closely tied to protecting mothers and infants from Group B streptococcus-associated disease.
